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Combination therapies that produce synergistic growth inhibition are widely sought after for
the pharmacotherapy of many pathological conditions. Therapeutic selectivity, however,
depends on the difference between potency on disease-causing cells and potency on non-
target cell types that cause toxic side effects. Here, we examine a model system of anti-
microbial compound combinations applied to two highly diverged yeast species. We find that
even though the drug interactions correlate between the two species, cell-type-specific
differences in drug interactions are common and can dramatically alter the selectivity of
compounds when applied in combination vs. single-drug activity—enhancing, diminishing,
or inverting therapeutic windows. This study identifies drug combinations with enhanced
cell-type-selectivity with a range of interaction types, which we experimentally validate using
multiplexed drug-interaction assays for heterogeneous cell cultures. This analysis presents a
model framework for evaluating drug combinations with increased efficacy and selectivity
against pathogens or tumors.
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Combination therapies are common in the treatment ofcancer and infectious diseases1,2. The use of drug combi-nations is motivated by evidence that they can achieve
cure rates superior to monotherapies3–5. Drug combinations may
be classified as synergistic or antagonistic when the observed
effect of the combination is greater or lesser, respectively, than is
expected based on the components’ effects as single agents6,7.
Consequently, much effort has been applied to the task of iden-
tifying synergistic combinations. Drug-interaction screens iden-
tify combinations with increased efficacy against specific cell lines
or phenotypes8, and computational methods aim to predict drug
synergies using chemogenomics9, genetic interactions10, and
physicochemical properties11,12.
However, consider a drug combination that is synergistic
against pathogenic or cancerous cells, but also has synergistic
toxicity to healthy host cells. In this case, there will be no benefit
to the therapeutic window, being the difference between the
dose required for the desired effect and the dose-limiting toxicity.
It is apparent that the efficacy of a synergistic combination is
entirely dependent on avoiding synergistic toxicity to unintended
cell types, as shown by Lehar et al.13 and reviewed in Bulusu
et al.14. Extending this idea, it has been debated that it is not
synergy itself that is pharmacologically useful, but differential
drug interactions between cell types, with the essential goal being
a more favorable interaction on the target cell type than on non-
target cell types15–17.
To test this idea, we implemented an experimentally tractable
system to systematically characterize how cell-type-specific drug
interactions affect the selectivity of combination therapies, by
profiling combinations of antifungal drugs applied to the yeast
species Saccharomyces cerevisiae and Candida albicans. Individual
differences in single-drug sensitivity constitute therapeutic win-
dows that select for single cell-type; however combinations of
drugs may have selectivity that varies from individual agents. We
used a sensitive screen to assess all 66 pairwise interactions of
12 antifungal small molecules (henceforth “drugs”) in C. albicans,
selected for direct comparison to a recent drug-interaction data
set in S. cerevisiae10 to determine differences in selectivity due to
single agents vs. combinations. Our model framework and sub-
sequent mixed culture assays show that therapeutic windows may
be enhanced or diminished by differential drug interactions.
Results
Precise assessment of drug interactions in two model yeasts.
We used a sensitive 8 × 8 checkerboard assay to assess all 66
pairwise interactions of 12 antifungal drugs (Table 1), in C. albi-
cans and S. cerevisiae10. This screen included drugs that target
DNA, cell wall, and metabolism as well as microtubule, phos-
phatase, and kinase inhibitors. All C. albicans experiments were
conducted in this study. Eight S. cerevisiae experiments were
newly conducted for this study: methyl methanesulfonate tested
against itself, bromopyruvate, calyculin A, dyclonine, fenpropi-
morph, haloperidol, rapamycin, and tunicamycin. Other experi-
mental data involving S. cerevisiae were obtained from Cokol
et al., 2011. Drug interactions were quantified by isobologram
analysis; briefly, each interaction score (α) for a drug pair was
calculated from the concavity of the isophenotypic contours that
map regions of similar growth inhibition across the drug-
concentration matrix.
To produce a reference that is by definition non-interacting,
we measured “self–self” interactions (drugs combined with
themselves) for ten drugs in both yeast species. This produced
interaction scores tightly distributed around zero (mean=−0.01,
std. dev.= 0.4) and defined 95% confidence intervals for
deviation from additivity. Synergy and antagonism were thereby
identified from these confidence intervals as α <−0.8 or α >+
0.8, respectively (Fig. 1a). Among the 66 drug combinations
tested in C. albicans, 20 synergistic and 27 antagonistic drug pairs
were identified (Fig. 1b).
Drug interactions were substantially, but not perfectly
conserved between C. albicans and S. cerevisiae (Spearman
correlation test r= 0.42, p-value= 1.8 × 10−4) (Fig. 2). Synergis-
tic, but not antagonistic, interactions significantly overlapped
in these related species (Fisher’s exact test, shared synergy:
p < 3 × 10−5, shared antagonism: p= 0.44). Notably, nine combi-
nations had highly divergent interactions, being synergistic in
one species and antagonistic in the other, suggesting that drug
combinations may be used to selectively inhibit a particular
cell type.
Cell-type selectivity of individual drugs. In order to understand
the relationship between drug interactions and cell-selective
inhibition, we first considered the selectivity of individual drugs.
The concentrations required for 50% growth inhibition of
C. albicans (IC50alb) and S. cerevisiae (IC50cer) were correlated
between species (r= 0.91, p < 10−13; Supplementary Fig. 1), but
most drugs had a therapeutic window for cell-selective inhibition
due to a two-fold or greater difference in IC50 between cell types.
We defined the selectivity score of a single-drug “A” (selectivityA)
as log2(IC50A,alb / IC50A,cer), such that a score of 0 indicates no
selectivity, and a score of 1 (or −1) denotes that twice (or half)
as much drug is required to inhibit C. albicans compared to
S. cerevisiae. Neither species was on average more drug-sensitive
or resistant than the other (no significant bias in selectivity scores
by sign test, p= 0.77). Benomyl and tunicamycin had the greatest
single-agent selectivity for C. albicans (3.8 and 2.4), while staur-
osporine and bromopyruvate were most selective for the growth
of S. cerevisiae (−1.7 and −1.6).
Drug interactions alter the selectivity of drug combinations.
We explored the impact of drug interactions on selectivity by
superimposing the isophenotypic contours from drug-interaction
experiments for each cell type, for the greatest level of inhibition
present in interaction data sets for both species (mean inhibitory
level= 0.31; std. dev.= 0.17). This visualization shows the
regions of selectivity between the drug-interaction contours and
allows the comparison of the selectivity of a combination with the
Table 1 Antifungal drugs used in the study
Drug Abbreviation PubChem
ID
alb
IC50
μg/ml
cer
IC50
μg/ml
Benomyl BEN 28780 130 9.6
Bromopyruvate BRO 70684 367 1086
Calyculin A CAL 5311365 2.1 2.2
Dyclonine DYC 3180 5.4 8.9
Fenpropimorph FEN 93365 0.1 0.3
Haloperidol HAL 3559 150 39
Methyl
methanesulfonate
MMS 4156 128 65
Pentamidine PEN 4735 27 73
Rapamycin RAP 5284616 0.15 0.04
Staurosporine STA 44259 0.2 0.6
Terbinafine TER 1549008 1.3 2.1
Tunicamycin TUN 6433557 1.7 0.3
All drug names are provided as well as abbreviations used in figures, PubChem ID and IC50
(µg/mL) for each drug tested in C. albicans (alb) and S. cerevisiae (cer). IC50 levels were
determined with yeast cells grown overnight and diluted in liquid culture to OD600= 0.1. S.
cerevisae and C. albicans concentration-response experiments were conducted in parallel to allow
for direct comparison of IC50 levels
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selectivity of individual drugs (Fig. 3, left panel). Selectivity of a
combination “A+ B” was determined similarly to the single-drug
selectivity, by the ratio of total drug concentrations required to
achieve an equal level of inhibition (Methods), where
selectivityA+B= log2(ICA+B,alb/ICA+B,cer), similar to a previously
defined selectivity index13 (Supplementary Fig. 2, upper panel).
Selectivity of self–self combinations was almost perfectly corre-
lated with their single-drug selectivity (r= 0.99, p= 3.6 × 10−5),
as expected from first principles.
Combination selectivity was unaltered when two drugs have
self–self or additive interactions (e.g., methyl methanesulfonate–
methyl methanesulfonate, Fig. 3a, left). However, for drug pairs
whose interactions vary between cell types, the selectivity of
the combination diverged from what is anticipated from its
component drugs. Pentamidine and staurosporine (PEN+ STA)
each preferentially inhibit C. albicans, and because they are
synergistic only in C. albicans, their combination enhances
selectivity for the growth of S. cerevisiae compared to either
single drug (Fig. 3b, left). Antagonistic interactions can also
enhance selectivity: methyl methanesulfonate and rapamycin
(MMS+ RAP) each preferentially inhibit S. cerevisiae, and in
combination produce an especially strong antagonism in
C. albicans which enhances their selectivity for the growth of
C. albicans (Fig. 3c, left). Differential interactions can both
strengthen and weaken selectivity: pentamidine and fenpropi-
morph (PEN+ FEN) both preferentially inhibit C. albicans, but
are antagonistic only in this cell type (Fig. 3d, left), which causes
diminished selectivity. A yet more striking result ensues from
the divergent interactions of calyculin A and dyclonine (CAL+
DYC): though each drug alone preferentially inhibits C. albicans,
their combination demonstrates such potent synergy only in S.
cerevisiae that their cell-type selectivity is inverted and is therefore
expected to select for the growth of C. albicans (Fig. 3e, left).
In order to compare the observed selectivity of combinations
with a null model, we approximated expected selectivity
(selectivityexp) as the combination selectivity that would be
observed if drugs A and B have additive interactions in both
species (Fig. 3, middle column) (Supplementary Fig. 2, lower
panel). Comparing expected and observed selectivity across the
complete set of drug combinations (example comparisons in
Fig. 3, right column), we found that 41 of 66 combinations
showed a significant difference in selectivity from additive
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Fig. 1 Drug-interaction screen results in C. albicans and S. cerevisiae. a Classification of drug interactions. Yeast cells were grown in a 2D grid with linearly
increasing concentrations of one drug on each axis. Representative experiments on C. albicans with growth curves are shown on a heat map for growth.
Drug interactions are assessed based on the concavity of isophenotypic contours. On the left, a “self–self” experiment is shown, wherein MMS is increased
on each axis. Such pairs are defined as additive and have linear isophenotypic contours. Drug pairs with concave (PEN-STA) or convex (MMS-RAP)
contours are defined as synergistic or antagonistic, respectively. b Drug-interaction experiments among all pairwise combinations of 12 drugs in C. albicans
and S. cerevisiae. Each subplot shows the growth level for each drug-concentration combination for C. albicans (green/teal) and S. cerevisiae (red/magenta).
Synergistic or antagonistic drug pairs are shown in yellow or blue boxes, respectively. Eight S. cerevisiae experiments were newly conducted for this study:
MMS tested against MMS, BRO, CAL, DYC, FEN, HAL, RAP, and TUN. Other experimental data involving S. cerevisiae were obtained from Cokol et al., 2011
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expectation based on self–self experimental variance (mean=
0.12, std. dev.= 0.10) (Supplementary Fig. 3). Thus, differential
drug interactions powerfully and quite commonly influence the
cell-type specificity of drug combinations, with the effect of
enhancing or diminishing therapeutic windows.
A common goal of drug combination design is to identify
drug pairs that synergistically inhibit the intended target cell type
while not producing synergy in other cell types. However, in
our study we observed that drug pairs with selectivity for the
growth of S. cerevisiae or C. albicans may be synergistic, additive
or antagonistic in either species (Supplementary Fig. 4). Accord-
ingly, drug combinations showing significant selectivity against
one species were not enriched for synergistic interactions in that
species (Fisher’s exact test, p > 0.05). We hypothesized that
selectivity is associated with the difference of drug interactions
between cell types. As a measure of drug-interaction difference,
we calculated delta-α, the difference of α scores between
C. albicans and S. cerevisiae (αalb−αcer). Delta-α scores are high
for pairs that are antagonistic against C. albicans and synergistic
for S. cerevisiae. Overall, there was a weak but significant
correlation (Spearman correlation test, r= 0.26, p= 0.02)
between cell-selective growth inhibition and delta-α (Supplemen-
tary Fig. 5). Therefore, we conclude that combinatorial selectivity
is influenced by the difference of two-drug interactions, neither
of which is necessarily synergistic.
In order to understand the effect of antimicrobial resistance
on therapeutic selectivity, we modeled the effects of 100-fold
resistance on selectivity metrics for all tested drug pairs.
We assumed that isophenotypic contours scaled with changes
in drug sensitivity18 and simulated resistance by multiplying
the minimal inhibitory concentration of one compound by 100
while preserving the shape of the drug-interaction isobole.
We observed that delta-α and sel–selexp are not significantly
correlated after simulating for resistance, suggesting that extreme
drug resistance is more influential on selectivity than variation
in drug interactions (Supplementary Fig. 5).
Validation of the selectivity model in co-cultures. Here we have
modeled the selectivity of combinations of drugs to different
fungal species. However, it is worth noting that sensitivity to drug
combinations was tested separately for each species, and not
together. To experimentally test the predicted selectivity change
due to drug interactions, we conducted co-culture assays with
fluorescently labeled strains of S. cerevisiae (mCherry+ , GFP−)
and C. albicans (GFP+ , mCherry−). We created a mixed culture
of two fluorescently labeled yeast species with approximately
equal number of cells from both species based on flow cytometry.
Mixed cultures were treated with two individual drugs or their
combination, incubated for 4 h, and assessed with flow cytometry
for the %C. albicans and %S. cerevisiae after treatment (Fig. 4a).
Drug-free controls were used as a reference to confirm single-
drug selectivity in the context of yeasts with different growth
rates. For each experiment, we computed a selectivity score
following the same formula as our model: log2(C. albicans/
S. cerevisiae). Importantly, since the growth rate of C. albicans is
faster than S. cerevisiae, it is expected that the %C. albicans in the
no drug condition will increase as compared to the initial ratio.
In these experiments, we used two-drug pairs with striking
phenotypes illustrated in Fig. 3: (i) CAL+DYC is synergistic in
both species but the synergy is stronger in S. cerevisiae. According
to our model, each of these drugs is expected to select for S.
cerevisiae, however the combination is expected to select for C.
albicans due to the inverted selectivity (Fig. 3e). Figure 4b
confirms the expectation that %C. albicans in the no drug
condition increases in the absence of selective pressure. In
agreement with the single-species experiments, the selectivity
scores for the CAL or DYC treated cultures were lower than the
no drug condition, indicating that each of these drugs selects
for S. cerevisiae growth. The combination CAL+DYC had a
higher selectivity score than the no drug condition, indicating
that the combination selects for C. albicans, thereby validating
the prediction of inverted selectivity under treatment with the
CAL+DYC combination. (ii) MMS+ RAP is antagonistic in
both species but the antagonism is stronger in C. albicans.
According to our model, each of these drugs is expected to select
for C. albicans, and the combination is expected to have a higher
selectivity for C. albicans than either drug, due to enhanced
selectivity by antagonism (Fig. 3c). In agreement with our model,
we observed that the selectivity score for MMS or RAP were
higher than the no drug condition, indicating that these drugs
individually select for C. albicans. The selectivity score for the
combination MMS+ RAP was higher than either single drug,
validating the predicted enhanced selectivity by antagonism
(Fig. 4c). All data collected for these experiments are presented
as Supplementary Fig. 6.
In order to extend our approach to alternative phenotypes, we
conducted drug-interaction experiments for fungicidality in
mixed cultures of fluorescent C. albicans and S. cerevisiae
(Fig. 5a). Among all 12 drugs studied, only MMS and RAP
exhibited acute strong fungicidal activity, hence, were amenable
to an assay of selective cell killing (Supplementary Fig. 7). This
combination is antagonistic in both C. albicans and S. cerevisiae,
but our analysis suggested enhanced selectivity for the growth
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Fig. 2 Conserved and divergent drug interactions between cell types. A
comparison of α scores in two yeast species. Based on the 95% confidence
interval of self–self interactions, interaction scores are interpreted as
follows: α <−0.8 as synergistic, α >+ 0.8 as antagonistic. Additive drug
combinations are within the magenta shaded area on the y-axis for S.
cerevisiae and within the green shaded area on the x-axis for C. albicans.
Self–self drug pairs are marked in blue and are centered on zero for both
axes, as expected. α scores in C. albicans and S. cerevisiae significantly
correlate, showing that drug interactions are conserved between these two
distantly related yeast species (Spearman correlation test r= 0.42, p-
value= 1.8 × 10−4). However, not all drug pairs followed this trend. At the
upper left and lower right quadrants are highly divergent drug pairs,
showing positive interactions in one species and negative interactions in the
other
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of C. albicans due to a difference in the strength of antagonism
(Supplementary Fig. 8). We assessed drug interactions for
fungicidal activity by co-culturing yeast strains in a 5 × 5
combination matrix of MMS and RAP for 1 h, plating cells and
enumerating cell killing by counting fluorescent colony-forming
units (CFU).
In strong agreement with the single-species drug-interaction
experiments (Fig. 3c), we observed that MMS+ RAP is
antagonistic for fungicidal activity in both species, but to a
stronger degree in C. albicans (Fig. 5b, c, Supplementary Fig. 9).
Consistent with the superimposed growth isoboles, we observed
that the low MMS-high RAP region is powerfully selective, killing
more than 99% of S. cerevisiae cells with less than 50% fungicidal
effect on C. albicans. Importantly, each of MMS and RAP
alone have similar fungicidal concentrations for both species,
and are incapable of exerting such effective cell-selective killing as
single agents.
Discussion
The ultimate goal of synergistic drug combinations is to enhance
the therapeutic window between efficacy and toxicity13. Drug-
interaction screens may identify combinations with increased
efficacy and selectivity for specific cell lines or phenotypes8.
In this study, we showed that while synergistic combinations
can indeed increase the cell-type selectivity of growth-inhibiting
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Fig. 3 Drug interactions may enhance, diminish or invert selectivity. Left panel: Observed isophenotypic contours of drug-interaction assays for S. cerevisiae
(magenta) and C. albicans (green) are overlaid in a 2D grid adjusted for relative concentration. We linearly transformed the isophenotypic contours for
drug-interaction assays so that S. cerevisiae’s isophenotypic contour intercepted both x and y axes at 1. Selectivity of a combination was determined by the
log ratio of the distance from the origin to the C. albicans vs. S. cerevisiae contours (log2(dalbicans/dcerevisiae)). Selectivity is therefore positive for drugs or
combinations that select for C. albicans. Middle panel: the middle panel demonstrates the null model for expected combination selectivity, assuming drug
pairs are additive. As in observed selectivity, expected selectivity is calculated based on the log ratio of distances from the origin with positive expected
selectivity corresponding to an expected selectivity for C. albicans, in the absence of synergistic or antagonistic drug interactions. Right panel: observed
(solid) and expected selectivity (dashed line) scores are overlaid. Green- or magenta- shaded regions represent observed C. albicans or S. cerevisiae
selectivity. Deviations from expected selectivity indicates a change in selectivity due to drug interactions. Five representative drug pairs are shown with
expected (additive) selectivity (a MMS+MMS), enhanced selectivity (b pentamidine and staurosporine and c MMS and rapamycin), diminished
selectivity (d fenpropimorph and pentamidine), and inverted selectivity (e calyculin A and dyclonine), compared to single-agent expected selectivity
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drugs12, the same is also true of antagonistic combinations,
because it is the difference in drug interactions between cell types
that enhances or diminishes the therapeutic window. Here, we
provided a proof-of-concept that drug interactions may shift
selectivity with respect to single-drug effects in mixed microbial
communities. Flow cytometry assessment of mixed yeast cultures
illustrated that a strong synergistic interaction between calyculin
A and dyclonine in S. cerevisiae selected for the growth of C.
albicans, as expected. However, for the combination of MMS and
rapamycin, the strength of antagonism selected for C. albicans,
both in growth and survival assays. Importantly, synergy does not
guarantee enhanced selectivity, with synergistic “off-target”
effects capable of diminishing or even inverting the therapeutic
selectivity.
We found that synergistic drug interactions for the 12 anti-
fungals tested were significantly conserved between these two
yeast species, while antagonistic interactions were not conserved.
A likely explanation for this is promiscuous synergy in which one
drug can affect the bioavailability of many other drugs, e.g., via
effects on membrane composition. Indeed, it seems likely that
much of the synergy for drugs targeting ergosterol biosynthesis in
this study (DYC, FEN, HAL, TER) is due to increased bioavail-
ability of partner drugs. Pentamidine has also been previously
identified as a promiscuously synergistic drug10, although the
mechanisms underlying this promiscuity remain unknown. By
contrast, only 3 of the 12 antifungals (BEN, BRO, STA) from our
panel have previously been identified as frequently participating
in antagonistic interactions19.
We used the checkerboard assay for a full appreciation of
interaction and selectivity as a proof-of-principle and found that
selectivity scores at θ= 45 are significantly correlated with
selectivity scores at θ= 23 and θ= 66. This indicates that a
simplified method for determining selectivity for equi-inhibitory
quantities of two drugs may provide a useful approximation of
the selectivity of drug combinations20–22.
Methods such as multiplex ELISA, PCR, and gene sequencing
allow cost-effective experiments. Drug-interaction assays are
generally conducted using a single microbe type or cell line. With
the co-culture method we described, the interactions for more
than one species can be measured in one experiment. Our study
uses a multiplexed drug-interaction assay, where the interaction is
simultaneously determined for multiple species in a hetero-
geneous culture. We propose that this approach could be applied
to mixed cultures of cancer cell lines tagged by DNA barcodes23
in order to efficiently identify drug combinations with selective
synergy against specific cancer genotypes.
Though differential drug interactions are common and, we
propose, important in the design of combinations, they were
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Fig. 4 Co-culture experiments validate the selectivity model predictions. a mCherry expressing S. cerevisiae and GFP expressing C. albicans cells were co-
cultured in single or combination drug treatments in liquid media and growth of each species was quantified using flow cytometry. b Selectivity scores
(log2(C. albicans/S. cerevisiae)) for mixed culture assays before treatment (t0), at no drug condition, CAL, DYC, and CAL+DYC co-culture experiments are
shown (n= 2). Also shown is the average selectivity from CAL and DYC conditions, which is the expected selectivity in the absence of drug interactions.
Comparison of the no drug condition to t0 shows that the amount of C. albicans in co-culture increases without any selective pressure, which is expected
due to the shorter doubling time of C. albicans. Comparison of CAL and DYC to no drug condition validates the model prediction of single-drug selectivity
for S. cerevisiae. Comparison of CAL+DYC to no drug condition indicates that the combination is selective for C. albicans, as predicted by the selectivity
model (inverted selectivity). c MMS and RAP both individually select for C. albicans. As predicted by the model, the MMS+ RAP combination has greater
selectivity for C. albicans (selectivity increase due to antagonism). (n= 2)
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observed against an overall strong conservation of drug interac-
tions between two species separated by hundreds of millions of
years of evolution24. Thus, these results provide a strong rationale
for screening drug interactions in model organisms or cell lines to
prioritize promising combinations for testing in related patho-
gens. We also predict that drug combinations that are synergistic
against a drug-sensitive cell type may remain therapeutically
relevant against drug-resistant strains whose genetic similarity
remains high. This prediction is in agreement with a recent study
that showed that gene deletions rarely lead to a change in drug
interactions among E. coli non-essential gene deletion strains25.
Similar reasoning predicts that drug combinations that are
synergistic against cancer cells may be accompanied with syner-
gistic toxic side effects given the inherent similarity between
cancer cells and normal cells from the same patient. While the
discovery of synergistic anti-cancer drug combinations is a
growing area of research, the therapeutic potential of synergistic
drug pairs must be pursued with caution considering the possi-
bility of enhanced toxicity. For example, the use of combination
immunotherapy in melanoma increases the objective response
rate by 14% but at the cost of more than doubling the rate of toxic
effects so severe that 36% of the patients discontinue treatment26.
We note that while our co-culture assay is an exciting means to
detect selectivity in heterogeneous cell cultures, our analytical
model is also applicable to other clinically relevant selectivity
considerations. Multiplexed drug-interaction assays may be
employed to detect selectivity under very specific conditions, for
example, commensal vs. pathogenic microbes that that may be
cultured together. These assays are especially useful to simulta-
neously measure drug interactions for drug resistant and sensitive
microbes in order to identify concentration regimes of the two-
drug space that specifically select against drug-resistant strains15.
However, in many therapies, toxicity occurs at tissues that are not
at the affected site of infection or disease, and are therefore not
amenable for co-culture. For example, ototoxicity arising from
aminoglycoside antibiotics27; nephrotoxicity arising from vanco-
mycin, aminoglycosides, and some beta-lactams28,29; cardiotoxi-
city from the chemotherapy doxorubicin and trastuzumab30;
or peripheral neuropathy associated with chemotherapies
including cisplatin, vincristine, and paclitaxel are all clinically
observed drug toxicities that could be modeled by this framework
of selectivity31.
By superimposing two systematic drug-interaction experiments
in distantly related yeast species, we generated a framework for
measuring selectivity of individual drugs and their combinations.
The analysis developed for this study provides a model for
assessing drug efficacy vs. side effects for combinations. This
strategy has immediate applications to the evaluation of ther-
apeutic potential of combination therapies or predicting adverse
side effects. Further studies may assess selectivity of drug com-
binations in cancer vs. normal cells to limit toxicity, or pathogenic
vs. commensal microbes (e.g., S. aureus vs. S. epidermidis) to
preserve the microbiome under antibiotic treatment.
Methods
Drug-interaction assessment. BEN, BRO, FEN, HAL, MMS, PEN, and TER were
purchased from Sigma-Aldrich. CAL, RAP, STA, TAC, and TUN were purchased
from AG Scientific; DYC was purchased from Toronto Research Chemicals
(Table 1). All drugs were dissolved in DMSO or water and stored at −20 °C. For C.
albicans strain SC5314, yeast cells were grown in YPD (1% yeast extract, 2% bacto-
peptone, 2% glucose) overnight and diluted to an OD600 of 0.1 in YPD with the
desired drug concentrations controlled for final solvent concentration of 2% DMSO
at 30 °C. Yeast cells were grown in liquid culture in an 8 × 8 grid on 96-well plates
with linearly increasing quantities of drug on each axis from zero drug to
approximately minimal inhibitory concentration. Plates were incubated for 16 h in
a Tecan Genios microplate reader; with OD595 readings every 15 min. Additional
drug-interaction assays (MMS tested against MMS, BRO, CAL, DYC, FEN, HAL,
RAP, and TUN), in S. cerevisiae strain BY4741 were conducted using the same
setup as described for C. albicans, with a duration of 24 h. The raw data for these
experiments are provided as a Supplementary Data 1 (also available at (https://doi.
org/10.6084/m9.figshare.6849068)). We used the area under OD595 curve of each
condition as a metric of cell growth, and standardized growth level to the drug-free
condition. Alternative growth metrics such as slope of growth curve and end-point
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Fig. 5Multiplexed fungicidal drug-interaction assay illustrates selectivity increase via antagonism. amCherry expressing S. cerevisiae and GFP expressing C.
albicans cells were co-cultured in 2D grids of drug combinations in liquid media and transferred to YPD-agar plates. After 48-hour incubation, plates were
photographed and cells enumerated with ImageJ software. b Bar charts of size proportional to cell number compared to the no drug control and color
representative of species (green: C. albicans, magenta: S. cerevisiae) are shown for each MMS-rapamycin combination tested. For each subplot, the top
dashed line represents CFUs equal to those observed for the no drug control and the second dashed line represents half the CFUs relative to those
observed for the control. Error bars represent ± S.E.M. of two independent experiment results, overlaid on the bar charts as dots (n= 2). The experiments
indicated with boxes correspond to four representative images of colonies post-incubation in variable drug conditions shown in c. c While rapamycin and
MMS are both toxic for these two yeast species, a low MMS-high rapamycin combination selects for the survival of C. albicans. The gray line is 15 mm, all
images are of the same size/scale
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05954-3 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3452 | DOI: 10.1038/s41467-018-05954-3 |www.nature.com/naturecommunications 7
OD strongly correlated with area under growth curve (Supplementary Fig. 10).
Drug-interaction scores obtained using variable growth metrics also strongly cor-
related (Supplementary Fig. 11).
A drug-interaction score (α) was defined by assessing the concavity of the
longest isophenotypic contour in the drug-interaction grid10. The Loewe additivity
model for drug interactions shows that isophenotypic contours are straight lines
(α= 0) for a drug “combined” with itself (a “self–self” combination), which serves
as the reference that defines non-interacting, or “additive” combinations6,32.
Selectivity assessment. To assess selectivity of drug combinations for a specific
yeast strain, isophenotypic curves at the greatest level of inhibition observed in
both species are superimposed on a drug-interaction grid adjusted for individual
strain concentration-response. Linear interpolation of the area under the growth
(OD595) curve was used to identify common inhibitory levels in the 8 × 8 check-
erboard of drug response. Considering drug-interaction contour plots in polar
coordinates, an angle reflects the relative fraction of each drug within a pair: as θ
changes from 0 to 90 degrees, the fraction of drug A increases and the fraction of
drug B decreases. The x- (θ= 0) and y- (θ= 90) intercepts represent the relative
inhibitory concentration of drug B and A alone. The distance (d) from the origin of
each point along the isophenotypic curve for each species at each angle represents
the relative amount of each drug combination to achieve the selected level of
inhibition. The selectivity score for C. albicans compared to S. cerevisiae is defined
as log2(dalbicans/dcerevisiae) for θ= 45. Selectivity scores at θ= 45 significantly cor-
related with selectivity scores at θ= 23 and θ= 66 (Spearman correlation test, r=
0.95, r= 0.94, respectively; Supplementary Fig. 12) and we therefore used selec-
tivity at θ= 45 for further comparisons of selectivity. Selectivity scores obtained
under variable growth metrics also strongly correlated (Supplementary Fig. 13). To
account for selectivity discrepancies between single drugs in a combination, we
computed an expected selectivity metric assuming additive interactions between
drugs in both species. Expected selectivity was assessed by connecting each species’
set of x- and y- intercepts with a straight line and computing a selectivity score
based on the relative distance from the origin to each contour for θ= 45.
Co-culture combination treatment assay and flow cytometry. S. cerevisiae
(mCherry) and C. albicans (GFP) were grown in YPD liquid culture overnight at
30 °C to OD600= 0.5, diluted to OD600= 0.1, and combined in approximately
equal number of cells based on flow cytometry. Cells were then co-incubated on
96-well plates in no drug, single drugs or 1:1 ratio combination of drugs. Final
concentrations in single-drug conditions were as follows: (CAL)= 4 μg/ml,
(DYC)= 500 μg/ml, (MMS)= 50 μg/ml, (RAP)= 1 ng/ml. Each well had a final
volume of 160 μl with a solvent concentration of 2% DMSO. Cells were incubated
for 4 h shaking at 900 rpm, at 30 °C. This incubation period maintains culture
heterogeneity as the proliferation rates as C. albicans doubling time is shorter than
S. cerevisiae (2 h vs 2.5 h). Strains with similar growth rates may be amenable to co-
culture for longer duration as in previous studies33. Cell/drug mixtures were
assessed for the relative abundance of each yeast species by flow cytometry. For all
experimental conditions, >20,000 events were acquired using an Attune NxT Flow
cytometer. Events were gated by forward and side scatter, and fluorescence dis-
tributions were calculated in FlowJo. Single cell cultures were used to define the
gates for GFP+ and mCherry+ yeasts, representing C. albicans and S. cerevisiae,
respectively.
Multiplexed fungicidal drug-interaction assay. S. cerevisiae (mCherry) and C.
albicans (GFP) were grown in YPD liquid culture overnight at 30 °C, diluted to
OD600= 0.02, and combined in equal volume and cell density (CFU/ml). These
yeasts had similar growth rates and concentration-responses to unlabeled strains.
Cells were then co-incubated on 96-well plates in 5 × 5 grid with two-fold serial
dilutions of MMS (max concentration, 2 mg/ml) and RAP (max concentration,
1 μg/mL) on each axis, including a zero-drug condition. Each well had a final
volume of 100 μl with a solvent concentration of 2% DMSO. Cells were incubated
for 1 h shaking at 600 rpm, at 30 °C in a ThermoFisher microplate shaker. Cell/
drug mixtures were then diluted 1/10 in YPD and 50 μl of diluted cells from each
condition were transferred to individual YPD-agar plates for enumeration.
After 48 h of incubation at 30 °C, plates were photographed with a custom-built
fluorescence imaging “Macrosope” device34 to visualize bright-field (1/10),
GFP (0.4”), and mCherry (3.2”) with aperture 5.6 and ISO 100. The colonies
were then enumerated using ImageJ colony counter (size: 400–6000 pixels2,
circularity: 0.85–1).
Cell lines. Wild-type C. albicans and S. cerevisiae were purchased from ATCC.
Fluorescent C. albicans and S. cerevisiae were kindly provided by the Cowen
Lab of University of Toronto and the Springer Lab of Harvard Medical School,
respectively.
Code availability. Codes to generate interaction and selectivity metrics are avail-
able upon request.
Data availability. The data that support the findings of this study are available
from the corresponding author upon request. Newly conducted drug-interaction
assays and growth assays are available at (https://doi.org/10.6084/m9.figshare.
6849068).
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